Precigen (PGEN) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Twist Bioscience (TWST) has outperformed Precigen (PGEN) over the past year, gaining 363.7% versus a gain of 136.0%. Over five years, PGEN leads with a +63.4% price change compared with +34.8% for TWST. Twist Bioscience is the larger company by market cap ($10.08 billion vs $2.72 billion), about 3.7 times the size, while Precigen is growing revenue faster (+146.7% vs +20.3%).
Twist Bioscience converts more of its revenue into profit, with a net margin of -20.6% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGEN | TWST |
|---|---|---|
| Share price | $7.60 | $152.05 |
| Market cap | $2.72B | $10.08B |
| 1-day change | +0.80% | -2.31% |
| YTD return | +81.82% | +379.35% |
| 1-year return | +136.02% | +363.71% |
| 5-year return | +63.44% | +34.80% |
| EPS (TTM) | $-1.04 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.68M | $376.57M |
| Revenue growth (YoY) | +146.73% | +20.32% |
| Net income (latest FY) | $-250.64M | $-77.67M |
| Gross margin | — | 50.72% |
| Operating margin | -1141.13% | -36.18% |
| Net margin | -2588.21% | -20.63% |
| 52-week high | $8.98 | $219.71 |
| 52-week low | $2.99 | $23.30 |
| Distance from 52-week high | -15.37% | -30.80% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +79.61% | -1.13% |
| Average volume | 5.03M | 2.04M |
| Shares outstanding | 358.04M | 66.30M |
| Employees | 160 | 979 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Twist Bioscience is about 3.7 times larger than Precigen by market value ($10.08B vs $2.72B).
- TWST has outperformed PGEN by 227.7 percentage points over the past year.
- Twist Bioscience is more profitable, keeping -20.6 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs +20.32%).
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Healthcare · Biotechnology · 160 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Healthcare · Biotechnology · 979 employees
PGEN vs TWST FAQ
Which is bigger, Precigen or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $10.08B compared with $2.72B for Precigen (PGEN).
Which stock has performed better over the past year, PGEN or TWST?
TWST returned +363.71% over the past 12 months, compared with +136.02% for PGEN (price return, excluding dividends). Past performance does not predict future results.
Are Precigen and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.